Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

3.73USD
3:19pm EST
Change (% chg)

$0.04 (+0.95%)
Prev Close
$3.70
Open
$3.74
Day's High
$3.74
Day's Low
$3.64
Volume
487,583
Avg. Vol
219,911
52-wk High
$6.30
52-wk Low
$3.64

Latest Key Developments (Source: Significant Developments)

Inovio Pharma Prices $65 Mln Convertible Senior Notes Offering
Thursday, 14 Feb 2019 07:00am EST 

Feb 14 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS PRICES $65.0 MILLION CONVERTIBLE SENIOR NOTES OFFERING.INOVIO PHARMACEUTICALS INC - PRICING OF ITS OFFERING OF $65.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 6.50% CONVERTIBLE SENIOR NOTES DUE 2024.  Full Article

Inovio Announces Appointments To Its Board Of Directors
Thursday, 3 Jan 2019 08:00am EST 

Jan 3 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO ANNOUNCES APPOINTMENTS TO ITS BOARD OF DIRECTORS.INOVIO PHARMACEUTICALS INC - SIMON X. BENITO, DIRECTOR SINCE 2003, NAMED CHAIRMAN OF BOARD.INOVIO PHARMACEUTICALS INC - LOTA ZOTH, FORMER MEDIMMUNE CFO, JOINS BOARD.INOVIO PHARMACEUTICALS INC - BENITO, FORMER MERCK VACCINES EXECUTIVE, HAS BEEN APPOINTED CHAIRMAN REPLACING AVTAR DHILLON WHO IS RETIRING.  Full Article

Inovio Pharmaceuticals Q3 Loss Per Share $0.27
Thursday, 8 Nov 2018 04:05pm EST 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.Q3 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.TOTAL REVENUE WAS $2.0 MILLION FOR THREE MONTHS ENDED SEPTEMBER 30, 2018, COMPARED TO $2.6 MILLION.  Full Article

Inovio Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250 Mln
Friday, 25 May 2018 04:39pm EDT 

May 25 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING.  Full Article

Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Tuesday, 9 Jan 2018 08:00am EST 

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS.INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION.INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO'S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY.  Full Article

Inovio Receives Milestone Payment From Medimmune
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2.  Full Article

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article

Inovio pharmaceuticals reports 2017 third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 third quarter financial results.Q3 loss per share $0.39.Q3 revenue $2.6 million versus $12.5 million.Q3 revenue view $9.4 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Inovio Pharmaceuticals - ‍as of Sept 30, 2017, cash and cash equivalents and short-term investments were $141.9 million versus $104.8 million as of Dec 31, 2016​.  Full Article

Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14
Thursday, 2 Nov 2017 06:23am EDT 

Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.  Full Article

Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection
Monday, 18 Sep 2017 08:00am EDT 

Sept 18 (Reuters) - Inovio Pharmaceuticals Inc :Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection.Inovio Pharmaceuticals Inc - Korean Ministry Of Food and Drug safety approved initiation of a study to evaluate GLS-5300.  Full Article